The in vitro choice_O.Nicolas_2013
-
Upload
la-unidad-de-toxicologia-experimental-y-ecotoxicologia-utox-pcb -
Category
Business
-
view
191 -
download
2
Transcript of The in vitro choice_O.Nicolas_2013
![Page 1: The in vitro choice_O.Nicolas_2013](https://reader033.fdocuments.in/reader033/viewer/2022052903/5579411dd8b42a31678b4810/html5/thumbnails/1.jpg)
RETOS Y TENDENCIAS EN DRUG DISCOVERY
JOSEP ORIOL NICOLÁS i PALLEJÀ, PhD CEO
![Page 2: The in vitro choice_O.Nicolas_2013](https://reader033.fdocuments.in/reader033/viewer/2022052903/5579411dd8b42a31678b4810/html5/thumbnails/2.jpg)
ABOUT US
Pharma
Food industry
Cosmetics
Chemical
25% FACTURACIÓN 10% EBITDA 97% CLIENTES INT.
![Page 3: The in vitro choice_O.Nicolas_2013](https://reader033.fdocuments.in/reader033/viewer/2022052903/5579411dd8b42a31678b4810/html5/thumbnails/3.jpg)
DISCOVERY OVERVIEW
![Page 4: The in vitro choice_O.Nicolas_2013](https://reader033.fdocuments.in/reader033/viewer/2022052903/5579411dd8b42a31678b4810/html5/thumbnails/4.jpg)
DISCOVERY OVERVIEW
RIESGO RIESGO Tóxico Tóxico
BENEFICIO BENEFICIO Terapeútico Terapeútico
RIESGO RIESGO Tóxico Tóxico
BENEFICIO BENEFICIO Terapeútico Terapeútico
RIESGO RIESGO Tóxico Tóxico Toxic RISK
BENEFICIO BENEFICIO Terapeútico Terapeútico BENEFIT Therapeutic
SAFETY A?
B? C? D?
A?
B?
C?
D?
Long and costly process to reach requirements of:
• Positive balance between therapeutic efficacy and safety • Optimal cost-effectiveness for administration in humans and
commercialization
![Page 5: The in vitro choice_O.Nicolas_2013](https://reader033.fdocuments.in/reader033/viewer/2022052903/5579411dd8b42a31678b4810/html5/thumbnails/5.jpg)
DISCOVERY OVERVIEW
![Page 6: The in vitro choice_O.Nicolas_2013](https://reader033.fdocuments.in/reader033/viewer/2022052903/5579411dd8b42a31678b4810/html5/thumbnails/6.jpg)
DISCOVERY OVERVIEW
• Pérdida de 56 M€ debido al negocio farmacéutico • Focalización en área de dolor
• Cierre de la compañía
• Focalización en área respiratoria y derma
![Page 7: The in vitro choice_O.Nicolas_2013](https://reader033.fdocuments.in/reader033/viewer/2022052903/5579411dd8b42a31678b4810/html5/thumbnails/7.jpg)
DISCOVERY OVERVIEW
![Page 8: The in vitro choice_O.Nicolas_2013](https://reader033.fdocuments.in/reader033/viewer/2022052903/5579411dd8b42a31678b4810/html5/thumbnails/8.jpg)
DISCOVERY OVERVIEW
44%
30%
13%
3%3% 2%
Facturación por país (Share %)
UK
Alemania
USA
España
Italia
Suiza
Italia
Bélgica
Singapur
Francia
Holanda
Finlandia
Japón
![Page 9: The in vitro choice_O.Nicolas_2013](https://reader033.fdocuments.in/reader033/viewer/2022052903/5579411dd8b42a31678b4810/html5/thumbnails/9.jpg)
DISCOVERY & DEVELOPMENT OPTIMIZATION
• FOCALIZACIÓN EN UN ÁREA TERAPÉUTICA CONCRETA
• DISMINUCIÓN DEL ENDEUDAMIENTO DERIVADO DE ACTIVIDADES DE R+D+I
• INCREMENTO DEL OUTSOURCING EN R+D
• DRUG REPROFILING
• IN/OUT LICENSING
• ENFERMEDADES HUÉRFANAS
• ADQUISICIÓN DE COMPAÑÍAS BIOTECNOLÓGICAS INNOVADORAS
• INVERSIÓN O APUESTA POR MÉTODOS “RENTABLES”: PREDICTORES DE RESPUESTA A FÁRMACOS, IN SILICO, IN VITRO.
![Page 10: The in vitro choice_O.Nicolas_2013](https://reader033.fdocuments.in/reader033/viewer/2022052903/5579411dd8b42a31678b4810/html5/thumbnails/10.jpg)
IN VITRO ADME MARKET
![Page 11: The in vitro choice_O.Nicolas_2013](https://reader033.fdocuments.in/reader033/viewer/2022052903/5579411dd8b42a31678b4810/html5/thumbnails/11.jpg)
IN VITRO ADME MARKET
• Recorte tiene su objetivo en RD
• Reestructuración tiene su objetivo en la RD
• Inversión tiene objetivo en la RD
• Rentabilización de la RD
![Page 12: The in vitro choice_O.Nicolas_2013](https://reader033.fdocuments.in/reader033/viewer/2022052903/5579411dd8b42a31678b4810/html5/thumbnails/12.jpg)
OUR PROPOSAL
![Page 13: The in vitro choice_O.Nicolas_2013](https://reader033.fdocuments.in/reader033/viewer/2022052903/5579411dd8b42a31678b4810/html5/thumbnails/13.jpg)
PROFITABILITY
![Page 14: The in vitro choice_O.Nicolas_2013](https://reader033.fdocuments.in/reader033/viewer/2022052903/5579411dd8b42a31678b4810/html5/thumbnails/14.jpg)
READY TO USE TECHNOLOGY™
“…EASING HANDLING AND SHIPPING…”
Patented solid shipping medium
Careful manipulation
Available in 24/96 multi-well format
OUR PRODUCTS: READY-TO-USE TECHNOLOGY
![Page 15: The in vitro choice_O.Nicolas_2013](https://reader033.fdocuments.in/reader033/viewer/2022052903/5579411dd8b42a31678b4810/html5/thumbnails/15.jpg)
Avoiding variability due to the cell culture
High reproducibility among batches
Careful manipulation
Available in 24/96 multi-well format
OUR PRODUCTS: ADVANTAGES
![Page 16: The in vitro choice_O.Nicolas_2013](https://reader033.fdocuments.in/reader033/viewer/2022052903/5579411dd8b42a31678b4810/html5/thumbnails/16.jpg)
Differentiated coculture Caco-2 and human goblet cells
MDCKII monolayer expressing MDR1, BCRP, BCRP_OATP2B1
Transporters
Differentiated Caco-2 cell barrier
HepG2 single transduced with different CYP450: 3A4, 1A2, 2E1,
2A6
OUR PRODUCTS: RANGES
![Page 17: The in vitro choice_O.Nicolas_2013](https://reader033.fdocuments.in/reader033/viewer/2022052903/5579411dd8b42a31678b4810/html5/thumbnails/17.jpg)
Viability study Definition and Development
Proof of Concept Validation Commercializat.
BBB KIT
Sebocyte cell model
Models for nanosafety
Preadyport-BCRP/OATP2B1
Preadyport-Other Transporters
Ready-to-use hepatocytes
Ready-to-use Adipocytes
PIPELINE
![Page 18: The in vitro choice_O.Nicolas_2013](https://reader033.fdocuments.in/reader033/viewer/2022052903/5579411dd8b42a31678b4810/html5/thumbnails/18.jpg)
www.readycell.com www.leitat.org [email protected]